

COVID-19 Pandemic Updates - April 20 2021

COMMUNITY RISK LEVEL: Low/Mod *	Prior Reporting Period (as of 4/13/21)	Current Reporting Period (as of 4/20/21)
Total Confirmed Cases	55,898	56,431
Deaths in FBC	590	595
Case Fatality Rate	1.06%	1.05%
Test % Positive Rate: NOTE: Due to insufficient testing numbers, FBC-HHS is unable to calculate a reliable test positivity rate that represents the level of community spread occurring FBC *Goal is to sustain a rate of <5% for at least 14 days		
SETRAC / FBC Hospital Data (Current as of 4/20/2021)		
FBC General Bed Usage	68	60
FBC ICU Bed Usage	18	18
% FBC ICU bed occupied by COVID+ Pts	15.9%	6.35%
TMC Data § (Current as of 4/19/2021)		
Effective Reproduction Rate R(t) <i>R(t) >1: indicates increasing viral transmission</i> <i>R(t) <1: indicates viral transmission is slowing down</i>	0.85	1.0
TMC % Positive Rate	4.6%	4.7%
% TMC ICU beds occupied by COVID+ Pts	13%	13%
TMC ICU Capacity (non-pandemic, Phase 1)	100%	100%
TMC ICU Capacity (combined, Phase 1&2)	80%	80%

***as of April 13, 2021**

§ TMC is seeing limited daily changes and will now be reporting on a weekly basis. They will change back, should the need arise.

Assessment/Comments

1. COVID-19 cases and hospitalizations continue to decline or remain flat.
2. Case Fatality Rate remains flat.

The Johnson & Johnson COVID-19 Vaccine Continues to Remain on "Pause"

April 13, 2021:

- FDA and the CDC halted administration of the Johnson & Johnson Covid-19 vaccine at federal sites and launched investigation of 6 US cases of cerebral venous thrombosis among women aged 18-49 given the one-shot vaccine
- All 6 developed this clotting disorder within one to three weeks of vaccination. One death reported so far
- This adverse reaction appears to be very rare (about 7 million people have received the J&J vaccine)
- Update from FDA/FDA expected later this week.
- *Update 4/20/21:* Johnson & Johnson announced on Tuesday that they will resume the rollout of their COVID-19 vaccine In Europe, following a statement from the European Medicines Agency (EMA) citing the benefit-risk ratio for the shot was still positive.

SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes

Nathaniel Moulson, Bradley J. Petek, Jonathan A. Drezner, Kimberly G. Harmon, Stephanie A. Kliethermes, Manesh R. Patel, Aaron L. Baggish

Originally published 17 Apr 2021 <https://doi.org/10.1161/CIRCULATIONAHA.121.054824>

Background: Cardiac involvement among hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is common and associated with adverse outcomes. The objective of this study was to determine the prevalence and clinical implications of SARS-CoV-2 cardiac involvement in young competitive athletes.

Conclusions: SARS-CoV-2 infection among young competitive athletes is associated with a low prevalence of cardiac involvement and a low risk of clinical events in short term follow-up.

Global COVID Deaths Top 3M

From MedPage Today (April 19, 2021):

- Global coronavirus deaths passed 3 million on Saturday, due to worsening crises in Brazil, India, and France. (*Associated Press*)
- The situation is so bad in Brazil that the government is recommending women delay pregnancy, warning that the new P.1 variant appears to be more severe for expectant mothers than the original virus. (*Reuters*)
- To that end, the Biden administration announced a \$1.7 billion investment to help U.S. states and jurisdictions fight SARS-CoV-2 variants.